The reMARQable Trial Will Study the nMARQ Multielectrode Irrigated Catheter for Treating Paroxysmal Atrial Fibrillation
By Mellanie True Hills and Melissa Moss
June 26, 2014
- Summary: The reMARQable trial will study the nMARQ multielectrode irrigated catheter for treatment of paroxysmal atrial fibrillation
- Reading time: 1–2 minutes
The reMARQable trial, sponsored by Biosense Webster, is studying the nMARQ system employing multiple electrodes on an irrigated catheter. There are two formats — a circular catheter with ten electrodes and a crescent catheter with seven electrodes.
The trial, in patients with symptomaticparoxysmal atrial fibrillation, will compare the nMARQ multi-electrode irrigated catheter to the currently-approved Biosense Webster ThermoCool irrigated catheter.
To learn more about the nMARQ catheter and the reMARQable study, including who is eligible and what centers are participating, see: